02142 HBM HOLDINGS-B
- 1.290
- +0.110+9.32%
HBM HOLDINGS-B News
Heplatinum Pharmaceutical-B (2142.HK): The advantages of the all-human antibody platform were obvious, and the performance turned a sharp loss into a profit
Heplatinum Pharmaceutical-B (2142.HK) Announcement Comment: B7H4X4-1BB Bispecific Antibody Authorizes HBICE Platform Continues to Incubate High Quality Products
Heplatinum Pharmaceutical-B (2142.HK): Continued innovation and commercialization is expected
Heplatinum Pharmaceutical-B (2142.HK): Commercial expansion continues to deepen clinical pipeline is progressing in an orderly manner
Heplatinum Pharmaceutical-B (2142.HK) Interim Review: R&D Costs Meet Expectations Technology Platform Cooperation Has Become a New Growth Point
Heplatinum Pharmaceutical-B (02142.HK) In-depth Research Report: Two New Drugs Will Soon Be Commercialized on Technology Platforms to Bring International Value
Heplatinum Pharmaceuticals (2142.HK): Technology is king, platform first
First coverage of Heplatinum Pharmaceutical-B (2142.HK): commercialization stage is approaching, R&D capabilities are endorsed by global pharmaceutical companies
Platinum Pharmaceutical-B (2142.HK): “and” Bi Sui Zhu and “Platinum” use their strengths to drive transformative new therapies
Heplatinum Pharmaceutical-B (2142.HK): Science-driven self-research+collaboration to build differentiated R&D pipelines
Heplatinum Pharmaceutical-B (2142.HK): HBM7022 authorized the value of AstraZeneca's global equity dual antibody technology platform to be highly recognized
and Platinum Pharmaceutical-B (2142.HK): Focus on differentiated therapies and diversified pipelines go hand in hand
Hebo Pharmaceutical Holdings Limited-B (2142.HK): IPO Report
IPO Report: Hebo Pharmaceutical Holdings Limited (2142.HK)
Analysis
Price Target
No Data
